Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC38 | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 13.3 | uM | 7468.085 | 0.9821 | 0.9751 | 1.4385 | |
| HCC38 | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 66.7 | uM | 7468.085 | 0.7059 | 0.5699 | 1.4385 | |
| HCC38 | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 333 | uM | 7468.085 | 0.0047 | -0.9520 | 1.4385 | |
| HCC38 | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.00256 | uM | 7469.084 | 0.9528 | 0.9531 | 2.0377 | |
| HCC38 | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.0128 | uM | 7469.084 | 0.9614 | 0.9617 | 2.0377 | |
| HCC38 | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.064 | uM | 7469.084 | 0.9147 | 0.9144 | 2.0377 | |
| HCC38 | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.32 | uM | 7469.084 | 0.9071 | 0.9066 | 2.0377 | |
| HCC38 | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1.6 | uM | 7469.084 | 0.9207 | 0.9205 | 2.0377 | |
| HCC38 | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 8 | uM | 7469.084 | 0.9028 | 0.9022 | 2.0377 | |
| HCC38 | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 40 | uM | 7469.084 | 0.8661 | 0.8638 | 2.0377 | |
| HCC38 | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 200 | uM | 7469.084 | 0.9368 | 0.9369 | 2.0377 | |
| HCC38 | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1000 | uM | 7469.084 | 0.0051 | -0.8498 | 2.0377 | |
| HCC70 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.000853 | uM | 7470.085 | 0.9333 | 0.8650 | 0.9880 | |
| HCC70 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.00427 | uM | 7470.085 | 0.9800 | 0.9596 | 0.9880 | |
| HCC70 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.0213 | uM | 7470.085 | 0.9853 | 0.9702 | 0.9880 | |
| HCC70 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.107 | uM | 7470.085 | 1.0046 | 1.0094 | 0.9880 | |
| HCC70 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.533 | uM | 7470.085 | 0.9705 | 0.9404 | 0.9880 | |
| HCC70 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 2.67 | uM | 7470.085 | 0.9799 | 0.9592 | 0.9880 | |
| HCC70 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 13.3 | uM | 7470.085 | 0.9077 | 0.8132 | 0.9880 | |
| HCC70 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 66.7 | uM | 7470.085 | 0.5447 | 0.0813 | 0.9880 | |
| HCC70 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 333 | uM | 7470.085 | 0.0230 | -0.9561 | 0.9880 | |
| Hs 578T | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.00256 | uM | 7473.084 | 1.0279 | 1.0272 | 2.0337 | |
| Hs 578T | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.0128 | uM | 7473.084 | 1.0632 | 1.0612 | 2.0337 | |
| Hs 578T | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.064 | uM | 7473.084 | 0.9858 | 0.9860 | 2.0337 | |
| Hs 578T | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.32 | uM | 7473.084 | 1.0137 | 1.0134 | 2.0337 |